What is Zacks Small Cap's Estimate for TNXP FY2025 Earnings?

Key Points

• Zacks Small Cap has lowered its FY2025 earnings per share estimate for Tonix Pharmaceuticals to ($14.01), down from a previous estimate of ($13.68).
• Tonix Pharmaceuticals reported a quarterly earnings of (3.86) per share, missing expectations, with a revenue of $2.00 million compared to forecasts of $2.60 million.
• Despite challenges, Tonix Pharmaceuticals maintains a consensus rating of "Buy" with a price target of $70.00.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Zacks Small Cap decreased their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a research note issued to investors on Monday, September 22nd. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of ($14.01) for the year, down from their prior forecast of ($13.68). The consensus estimate for Tonix Pharmaceuticals' current full-year earnings is ($1,762.50) per share.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($3.86) EPS for the quarter, missing the consensus estimate of ($3.10) by ($0.76). The company had revenue of $2.00 million for the quarter, compared to analysts' expectations of $2.60 million. Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 57.93%.

TNXP has been the topic of several other reports. Alliance Global Partners reiterated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Tonix Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $70.00.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ:TNXP opened at $25.29 on Wednesday. The company has a market cap of $221.69 million, a P/E ratio of -0.64 and a beta of 1.86. Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $130.00. The business's 50-day simple moving average is $37.91 and its 200 day simple moving average is $30.39.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new position in Tonix Pharmaceuticals during the 4th quarter worth $66,000. IFP Advisors Inc acquired a new stake in shares of Tonix Pharmaceuticals in the first quarter valued at $179,000. Jane Street Group LLC lifted its holdings in shares of Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after buying an additional 1,635,119 shares during the period. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at $162,000. Finally, Rhumbline Advisers acquired a new stake in shares of Tonix Pharmaceuticals in the first quarter valued at $244,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.